Khorana score for cancer-associated thrombosis (also searched with possessive/alternate eponym spelling where applicable, ICD-10: Z13.89, I82.40) is a validated clinical prediction tool utilized in ambulatory oncology to stratify patients initiating systemic chemotherapy according to their absolute risk of developing venous thromboembolism (VTE) 1,2. Cancer-associated thrombosis (CAT) represents a leading cause of morbidity and mortality in malignant disease, surpassed only by cancer progression itself 1,5. Developed in 2008 by Alok A. Khorana and colleagues, the Khorana risk score incorporates five readily available pre-chemotherapy clinical and laboratory parameters: primary tumor site, pre-chemotherapy platelet count, hemoglobin level or use of erythropoiesis-stimulating agents, leukocyte count, and body mass index 1,6. By categorizing patients into low-risk (score 0), intermediate-risk (score 1–2), and high-risk (score $\ge 3$) tiers, the scoring system guides evidence-based decisions regarding primary pharmacological thromboprophylaxis, thereby optimizing the therapeutic window between thrombotic prevention and major hemorrhagic complications 2,4.

Etiology & Risk Factors

  • Primary Tumor Site: Malignancies vary markedly in their baseline thrombogenic potential; high-risk anatomical sites include pancreatic and gastric cancers (assigned 2 points), whereas lung, lymphoma, gynecologic, genitourinary (excluding prostate), and breast cancers carry intermediate risk (assigned 1 point) 1,7.
  • Hematological Biomarkers: Pre-chemotherapy complete blood count abnormalities reflect tumor-induced cytokine release (e.g., IL-6, G-CSF) and thrombopoiesis, specifically leukocytosis ($> 11 \times 10^9/\text{L}$), thrombocytosis ($\ge 350 \times 10^9/\text{L}$), and anemia (hemoglobin $< 10\text{ g/dL}$) or administration of erythropoiesis-stimulating agents 1,4.
  • Patient-Specific Anthropometric Factors: Obesity, defined as a body mass index (BMI) $\ge 35\text{ kg/m}^2$, independently increases venous stasis and systemic inflammatory signaling, contributing 1 point to the aggregate score 2,6.
  • Systemic Oncologic Therapy: Initiation of specific chemotherapeutic regimens (e.g., platinum-based agents, anti-angiogenic therapies, immunomodulatory drugs, and tamoxifen) substantially amplifies the baseline risk of thrombosis 4,7.
  • Acquired Patient Comorbidities: Advanced age, prior history of VTE, central venous catheterization, renal impairment, and acute infection or hospitalization significantly compound the baseline risk of CAT 3,5.

Pathophysiology

Malignancy establishes a profoundly prothrombotic milieu through mechanisms classically described by Virchow’s triad: alterations in blood composition (hypercoagulability), hemodynamic stasis, and endothelial injury 3,7. Tumor cells aberrantly express and shed tissue factor (TF)-bearing microparticles into the circulation, which bind factor VIIa and trigger the extrinsic coagulation cascade, generating robust thrombin bursts 1,4. Concurrently, cancer cells secrete mucins, podoplanin, and pro-inflammatory cytokines that directly activate platelets, monocytes, and neutrophils, leading to neutrophil extracellular trap (NET) formation and intravascular fibrin deposition 3,7. Systemic inflammation downregulates physiological anticoagulant mechanisms, notably suppressing antithrombin III and protein C pathways, while concurrent physical factors—such as tumor compression of major pelvic or abdominal veins, prolonged immobility, and indwelling central venous catheter surfaces—promote venous stasis and direct endothelial trauma 2,5.

Khorana score for cancer-associated thrombosis — Pathophysiological Cascade & Clinical Flowchart 1 Pre-Chemotherapy Initiation Baseline clinical assessment and risk factor identification including primary tumor site, BMI, and complete blood count 2 Scoring Calculation Summation of clinical and laboratory variables yielding a cumulative Khorana risk score (0 to >= 3) 3 Hypercoagulable State Activation Tumor-induced procoagulant release, tissue factor expression, and leukocytosis predisposing to micro- and macro-vascular thrombosis 4 Venous Thromboembolism Manifestation Acute clinical presentation of deep vein thrombosis (DVT) or pulmonary embolism (PE) during systemic chemotherapy 5 Targeted Primary Prophylaxis & Management Initiation of direct oral anticoagulant prophylaxis (apixaban/rivaroxaban) or therapeutic anticoagulation (LMWH/DOACs) to mitigate mortality

Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients may present with asymptomatic incidental VTE discovered during routine staging computed tomography (CT) scans, or symptomatic presentations including unilateral lower extremity pain, progressive calf or thigh swelling, pitting edema, erythema, and superficial venous cord formation in deep vein thrombosis (DVT) 1,5. When complicated by pulmonary embolism (PE), patients commonly report acute-onset dyspnea, pleuritic chest pain, tachypnea, tachycardia, hemoptysis, or unprovoked syncope 3,4.
  • Physical Examination & Named Clinical Signs: Examination of the lower extremities frequently reveals an asymmetric calf circumference discrepancy ($> 3\text{ cm} measured 10\text{ cm}$ below the tibial tuberosity), palpable tender cords, and localized warmth 1,4. Classical maneuvers such as Homans sign (calf discomfort on passive dorsiflexion of the foot), Pratt's sign (tenderness on compression of the posterior calf), and Moses sign (pain on squeezing the calf muscles) demonstrate limited sensitivity and specificity but are historically noted 2,6. In massive PE, physical findings may include elevated jugular venous pressure, an accentuated pulmonic component of the second heart sound (P_2), right ventricular heave, hypotension, and signs of acute right heart failure 3,7.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationCompression venous ultrasonography (CUS) with color Doppler demonstrating lack of vein compressibility and intraluminal thrombus for DVT; Contrast-enhanced multidetector CT pulmonary angiography (CTPA) showing sharp filling defects in the pulmonary arterial tree for PE 1,4.
Laboratory PanelComplete blood count (confirming leukocytosis $> 11 \times 10^9/\text{L}$, thrombocytosis $\ge 350 \times 10^9/\text{L}$, or anemia $< 10\text{ g/dL}$ for Khorana scoring), elevated D-dimer (high sensitivity but limited specificity in active malignancy), coagulation profile (PT/INR, aPTT, fibrinogen), and comprehensive metabolic panel to assess baseline renal and hepatic function prior to anticoagulation 2,5.
Imaging / Radiology (X-ray, US, CT, MRI)Chest radiography frequently normal or revealing non-specific abnormalities (e.g., atelectasis, small pleural effusion, Westermark sign, or Hampton hump) in PE; Ventilation-Perfusion (V/Q) scan reserved for patients with renal impairment or iodinated contrast allergy; Transthoracic echocardiography demonstrating McConnell sign (RV free wall akinesia with apex sparing) in acute massive PE 3,6.
ECG / Histopathology / ProceduralElectrocardiogram demonstrating sinus tachycardia, classic S1Q3T3 pattern, new incomplete or complete right bundle branch block, and T-wave inversions in leads V1–V4 during acute PE; histopathologic confirmation of underlying malignancy and thrombus organization 1,7.

Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Primary Site of CancerVery high risk (stomach, pancreas) = 2 points; High risk (lung, lymphoma, gynecologic, genitourinary excluding prostate, breast) = 1 point; Other sites = 0 points 1,2.
Pre-Chemotherapy Platelet Count$\ge 350 \times 10^9/\text{L}$ = 1 point; $< 350 \times 10^9/\text{L}$ = 0 points 1,4.
Hemoglobin Level / ESAsHemoglobin $< 10\text{ g/dL}$ or use of red cell growth factors / erythropoiesis-stimulating agents = 1 point; $\ge 10\text{ g/dL}$ = 0 points 2,6.
Pre-Chemotherapy Leukocyte Count$> 11 \times 10^9/\text{L}$ = 1 point; $\le 11 \times 10^9/\text{L}$ = 0 points 1,3.
Body Mass Index (BMI)$\ge 35\text{ kg/m}^2$ = 1 point; $< 35\text{ kg/m}^2$ = 0 points 2,5.
Khorana Risk Tier & VTE RateScore 0 (Low Risk): VTE rate ~0.8–1.5% at 2.5 months (observation/no routine prophylaxis); Score 1–2 (Intermediate Risk): VTE rate ~1.8–3.0% (shared decision-making); Score $\ge 3$ (High Risk): VTE rate ~6.7–13% (strong recommendation for primary oral anticoagulant thromboprophylaxis) 2,4,6.

Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Chronic Venous Insufficiency & LymphedemaBilateral dependent pitting edema, skin hyperpigmentation (lipodermatosclerosis), absence of acute calf tenderness, and fully compressible veins without intraluminal thrombus on duplex ultrasound 1,4.
Baker's Cyst RuptureHistory of posterior knee pain extending into the calf, crescent sign of ecchymosis around the malleolus, palpable popliteal fluid collection, and normal venous compressibility on musculoskeletal ultrasound 3,5.
Pneumonia & Pleural EffusionFever, productive cough, focal pulmonary consolidations on chest radiography, elevated inflammatory markers (CRP, procalcitonin), and absence of vascular filling defects on CTPA 2,6.
Musculoskeletal Strain / Hematoma明確 history of localized trauma or physical exertion, point tenderness over muscle bellies rather than venous tracts, intact venous flow dynamics, and no structural vascular occlusion 1,7.

Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Hemodynamic stabilization in acute massive PE requiring supplemental oxygen to maintain $SpO_2 \ge 92\%$, aggressive fluid restriction, and vasopressor support (norepinephrine infusion titrated to maintain mean arterial pressure $\ge 65\text{ mmHg}$) 3,5. Systemic thrombolysis (alteplase 100 mg IV infusion over 2 hours) or catheter-directed mechanical thrombectomy is indicated for hemodynamically unstable patients with right ventricular failure and acceptable bleeding risk 4,7.
  • First-Line Medical / Pharmacological Therapy:
    • Primary Thromboprophylaxis (Ambulatory High-Risk, Khorana Score $\ge 2$): Direct oral anticoagulants (DOACs) are recommended for eligible cancer outpatients initiating systemic chemotherapy. Regimens include Apixaban 2.5 mg PO twice daily or Rivaroxaban 10 mg PO once daily for the duration of chemotherapy, provided bleeding risk is low and no significant drug interactions exist 5. Alternative: Low Molecular Weight Heparin (LMWH) such as Enoxaparin 40 mg SC once daily or Dalteparin 5,000 IU SC once daily 2,4.
    • Treatment of Established Cancer-Associated Thrombosis (CAT): Acute management requires anticoagulation for at least 6 months. First-line agents include DOACs (Apixaban 10 mg PO twice daily for 7 days, followed by 5 mg PO twice daily; Edoxaban 60 mg PO once daily following initial LMWH run-in of $\ge 5$ days; Rivaroxaban 15 mg PO twice daily for 21 days, followed by 20 mg PO once daily) or weight-based LMWH (e.g., Enoxaparin 1 mg/kg SC every 12 hours or 1.5 mg/kg SC once daily) 5.
  • Surgical & Interventional Indications: Inferior vena cava (IVC) filter placement is strictly reserved for patients with absolute contraindications to therapeutic anticoagulation (e.g., active major visceral bleeding, recent intracranial hemorrhage) or recurrent thromboembolism despite optimal therapeutic anticoagulation 3,6.

Complications & Prognosis

  • Acute & Chronic Complications: Post-thrombotic syndrome (PTS) characterized by chronic limb pain, heaviness, edema, and venous ulceration; chronic thromboembolic pulmonary hypertension (CTEPH) resulting from unresolved pulmonary emboli; major hemorrhagic complications (gastrointestinal or intracranial bleeding) associated with anticoagulant therapy; recurrent VTE events; and significantly increased all-cause mortality linked to both thrombotic episodes and advancing malignant disease 1,3,5.
  • Prognostic Factors: Prognosis is dictated primarily by tumor stage, performance status, baseline Khorana risk score tier, and the occurrence of clinical thrombotic events, which independently double mortality rates in oncology cohorts 2,6. The presence of incidental VTE carries prognostic implications comparable to symptomatic VTE, reinforcing the clinical necessity of rigorous risk stratification and proactive management 1,4.